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Abstract
Background The day-to-day variability in the number of
reflux episodes and symptoms of gastro-esophageal reflux
disease is high; therefore, the assessment of reflux disease
based on 24-h monitoring may be inaccurate.
Aims The aim of the study was to compare prolonged
(48 h) and standard (24 h) pH-impedance monitoring (pH-
MII).
Methods Fifty-four consecutive patients with typical and
atypical reflux symptoms underwent 48-h pH-MII. Acid
exposure time (AET), total number of reflux episodes (TR),
number of symptoms, and symptom association probability
(SAP) were analyzed after the first 24 h and compared with
the results obtained during 48 h of monitoring.
Results The differences between the fractions of patients
with normal and abnormal total AET and TR on both days
were not significant. The percentage of patients with
positive SAP was 57.9 % at 24 h and 71.9 % at 48 h
(difference: 14.81 %, 95 % CI 0.7–21.29, P \ 0.05). There
were ten patients (10/54, 18.5 %) with positive SAP after
48 h that had been negative in the first 24 h. In comparison
to 24 h monitoring, patients reported a significantly
increased number of various symptoms correlated with
reflux after 48 h.
Conclusions Extending pH-MII monitoring to 48 h does
not improve the detection of abnormal acid exposure.
However, it does increase the fraction of patients with
positive symptom-reflux association by as much as 18.5 %.
Keywords Esophageal pH monitoring  Gastro-
esophageal reflux  Impedance  Symptom assessment
Introduction
Reflux monitoring with esophageal 24-h pH-metry has
traditionally been based on measuring the abnormal
esophageal acid exposure time (AET) and the number of
acid reflux episodes [1]. However, the sensitivity of the pH
test is limited by the day-to-day variability in AET. Up to
16 % of patients with a positive 24-h pH monitoring had
negative results on the follow-up 24-h pH-metry [2].
Moreover, up to 25 % of subjects with erosive esophagitis
have a false negative pH-metry result, and the number of
negative pH tests may be even higher in patients with non-
erosive reflux disease (NERD) [3]. The false negative 24-h
pH-metry may be a consequence of changes in daily
activities and food consumption during a pH test, resulting
in detecting a lower number of acid reflux episodes and
symptoms. In some patients, these changes may be due to a
poor tolerance to the trans-nasal placement of the pH
catheter [4, 5]. These limitations have been overcome by
the development of a wireless esophageal pH test that also
allows for prolonged pH recording. Extending the moni-
toring period from 24 to 48 h increases the sensitivity of
the pH test by 10–26 %, thereby improving symptom
analysis as an increased number of symptoms is reported
by patients with a longer duration of recording. Although
the wireless system is generally well tolerated, the disad-
vantages include: chest discomfort, premature detachment,
necessity of using endoscopy, and poor availability [6–9].
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Additionally, the potential limitations of pH-tests are: (1)
low sensitivity in detecting reflux with pH above 4.0 and
(2) lack of the assessment of correlation of symptoms with
non-acid reflux episodes.
Combined pH with impedance monitoring is the only
available method with the ability to quantify acid and non-
acid reflux, which increases the diagnostic yield of gastro-
esophageal reflux disease (GERD) by 15–20 % [10–13].
Compared to pH-metry-only evaluation, the greatest asset
of pH-impedance monitoring is the possibility to assess
those patients with persistent symptoms despite proton
pump inhibitor (PPI) therapy [12–17]. pH-impedance is
also helpful in evaluating patients with NERD and extra-
esophageal reflux symptoms [13, 16, 18–21]. Both groups
represent the most problematic patients in clinical practice.
Taking into consideration the day-to-day variability in
reflux and symptoms, and the occurrence of non-acid
reflux, the 24- or 48-h pH-only monitoring can be inac-
curate in assessing some patients with refractory symptoms
despite PPI therapy or NERD patients with extraesophageal
reflux symptoms. Therefore, the aim of our study was to
compare the prolonged (48 h) pH and impedance moni-
toring (pH-MII) with a standard 24-h test.
Methods
Patients
We performed a retrospective analysis of prolonged pH
and impedance tests that were conducted in 57 consecutive
patients. The patients were referred to the Department of
Gastroenterology and Internal Medicine at the Medical
University of Bialystok for pH-impedance monitoring due
to persistent GERD symptoms despite PPI therapy, and for
the evaluation of extraesophageal GERD symptoms. The
patients reported typical (heartburn, regurgitation) and
atypical (chest pain, abdominal pain, belching, cough)
reflux symptoms. In patients exhibiting persistent symp-
toms despite PPI treatment for a period of at least 2 months
(with previously documented GERD: typical reflux syn-
drome, and/or esophagitis, and/or abnormal acid exposure
off PPI therapy), pH-MII monitoring was performed on the
continued twice daily standard dose of PPI therapy. In
patients who were referred for the evaluation of potential
association of extraesophageal reflux symptoms with
GERD, to exclude or to confirm GERD as a cause of
symptoms, pH-MII monitoring was performed off PPI
therapy. Other causes of extraesophageal symptoms were
excluded by cardiologists, allergologists, and laryngolo-
gists before referral. Exclusion criteria included a history of
previous gastric or esophageal surgery, and esophageal
motility disorders. Upper gastrointestinal endoscopy was
performed in all patients within the last 12 months or
before pH-MII monitoring. Both the study protocol and all
the procedures were approved by the Local Ethics Com-
mittee of the Medical University in Bialystok, and all the
subjects gave their informed written consent before the
start of any procedure.
pH-Impedance Monitoring
pH-MII monitoring was performed after an overnight fast
using a Sleuth multi-channel intraluminal impedance system
(Sandhill Scientific Inc., Highland Ranch, CO), consisting of
a portable data logger and a catheter with one pH electrode
and eight impedance electrodes at 3, 5, 7, 9, 15, and 17 cm
from the tip, positioned 5 cm above the upper border of the
lower esophageal sphincter (LES) as determined by
manometry. The patients were instructed to press the event
marker button on the data logger whenever they experienced
a symptom and to fill out a diary indicating the time of the
symptom, the start and end times of their meals, changes in
body position (recumbent, upright), and time of PPI intake.
The patients were asked to consume at least three meals
during the day and encouraged to try to maintain their
normal daily routine. Meal periods were excluded from
analysis. All data was collected on 256 MB compact flash
cards. After 48 h of monitoring (the time of monitoring
included two nights), the data was downloaded onto a
computer and analyzed using a semi-automated software
system (BioView, Sandhill Scientific) and verified manually.
Data Analysis
The following data was analyzed: acid exposure time
(AET), acid clearance time (ACT), bolus clearance time
(BCT), number of reflux episodes (TR), number of reflux
episodes reaching 15 cm above LES (proximal reflux), and
the number of symptoms. Total acid exposure time (% total
time at pH below 4.0) of less than 4.2 % over 24 h was
considered normal for patients off PPI therapy, while less
than 1.3 % was considered a norm for patients on PPI
therapy, in accordance with previously published criteria
[22, 23]. Reflux episodes were classified as acid, weakly
acidic, or weakly alkaline in accordance with previously
reported criteria: (1) acid reflux: impedance-detected reflux
with nadir pH below 4; (2) weakly acidic reflux: reflux with
nadir pH between 4 and 7; (3) weakly alkaline reflux:
reflux with nadir pH above 7.
The number of symptoms related to acid reflux and
weakly acidic reflux, as well as weakly alkaline reflux was
calculated. Symptom-reflux association was performed
using SI (symptom index) and SAP (symptom association
probability) indexes for each patient. Separate analysis was
performed for each individual symptom if the patient
Dig Dis Sci (2013) 58:2556–2563 2557
123
recorded symptoms of different types. The patient was
considered as a patient with positive symptom-reflux asso-
ciation if he/she had at least one type of symptom correlated
with reflux. For each patient, the number of different types
of symptoms with positive reflux association was calculated.
The SI and SAP were calculated according to the formula
described by other authors [24, 25]. The SI was defined as
the percentage of reflux-related symptoms preceded by
reflux (with 2-min time window). The SAP was calculated
by dividing the data set into consecutive 2-min periods. We
investigated whether reflux episodes occurred in each 2-min
segment and in the 2-min period before each symptom. SAP
indicates the statistical probability that the observed symp-
tom-reflux association could have occurred by chance. The
cutoff value for a positive SAP test was SAP C95 % and for
the SI test C50 %.
All parameters were analyzed separately for the first and
second 24 h of monitoring (day 1 and day 2). Data mea-
sured during the first 24 h were compared to the final
outcome after 48 h of monitoring (day 1 ? 2). All analyses
were performed on all the patients participating in the study
and, additionally, on two subgroups of patients: off PPI
therapy and on PPI therapy.
At the end of the pH-impedance test, all patients were
asked to answer the following three questions: ‘‘Did you
tolerate the study well?’’, ‘‘Did you experience any side
effects associated with the probe?’’, and ‘‘Would you do
the test again?’’.
Statistical Analysis
Not-normally distributed data obtained from the subjects
were summarized by median values and interquartile ran-
ges (IQRs) and comparisons between them on day 1 and
day 2 were performed using the Wilcoxon matched-pairs
signed-rank test. The differences between the fractions of
patients (expressed as a percentage with a 95 % confidence
interval [CI]) with positive and negative SI and SAP,
normal and abnormal AET, and normal and abnormal total
number of reflux episodes in each period of the study time
were performed using the McNemar exact testing. Differ-
ences were considered statistically significant when
P \ 0.05. All statistical analyses were performed using
STATA statistical software.
Results
Patients and Technical Success of 48-h pH-MII
Monitoring
Fifty-seven patients (median age 49, 20–72 years, 32
females) agreed to undergo pH and impedance monitoring
for 48 h. One patient did not complete the two-day-long
study due to the failure of the monitoring device battery.
One patient was excluded from analysis due to a technical
problem with the pH electrode. In one patient, the probe
was disconnected from the Sleuth device at night. There-
fore, complete two-day-long recordings were available for
54 patients (94.7 %).
In 33 patients, pH-MII monitoring was performed off
PPI therapy. Endoscopy showed erosive esophagitis in
eight of those patients (8/33; 24.2 %; grade A in six
patients and grade B in two patients according to Los
Angeles classification), ESEM (endoscopically suspected
esophageal metaplasia) in one patient (1/33; 3 %), and
hiatal hernia in five patients (5/33; 15.2 %).
In 21 patients with previously diagnosed GERD and
refractory reflux symptoms, pH and impedance monitoring
were performed on PPI therapy. Among those 21 patients
without erosive esophagitis, four patients (4/21; 19 %) had
hiatal hernia.
pH-MII monitoring was well tolerated by all subjects
with the exception of eight patients (8/54; 14.8 %): three
patients had throat pain (two on day 1 and one on day 2)
and five experienced nasal discomfort during monitoring
(two on day 1 and three on day 2). Importantly, 76 % of the
patients would do the test again. The median duration of
recording was 45.82 h (IQR 45.13–47.09).
Reflux Episodes
The characteristics of reflux episodes are presented in
Table 1. Compared with reflux episodes on day 1, reflux
episodes on day 2 had similar characteristics except for the
median number of acidic reflux episodes, which occurred
more frequently on day 1. This difference was detectable in
patients on PPI therapy, but not in patients who were off-
therapy (data not shown). The abnormal total number of
reflux episodes on both day 1 and day 2 was reported by
29.6 % (16/54) of patients. Furthermore, 64.8 % (35/54)
had normal total number of reflux episodes on both days of
monitoring. There were no significant differences between
the fractions of patients with abnormal and normal number
of reflux episodes documented on day 1 and day 2 (1.85 %;
95 % CI -4.51 to 5.46; P = 1.000; Fig. 1).
Esophageal Acid Exposure Time, Acid Clearance
Time, and Bolus Clearance Time
The median total AET, ACT, and BCT on day 1 were
similar to day 2 in all patients (Table 2). Overall, 81.5 %
(44/54) of patients had similar AET on both days 1 and 2.
There was no concordance of AET measurement between
both days in 18.5 % (10/54) of patients (Fig. 1). There
were no significant differences between the fractions of
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patients with normal and abnormal total AET documented
on day 1 and day 2 (7.41 %; 95 % CI -5.65 to 16.05 %;
P = 0.3438).
Symptoms Reported by Patients
There were only two patients who did not report symptoms
during the first day, but had symptoms during the second
day of monitoring. One patient with symptoms on day 1 did
not report symptoms on day 2. Overall, a median number
of 11 (IQR 6–26), 9.5 (IQR 5–32), and 21 (IQR 10–58)
symptoms per patient was reported during day 1, day 2, and
after 2 days of monitoring, respectively. The following
symptoms were reported by the patients: heartburn (37 %;
20/54), regurgitation (48 %; 26/54), abdominal pain
(46.3 %, 25/54), chest pain (42.6 %, 23/54), and belching
(59 %; 32/54).
Symptom-Reflux Association in All Patients
When symptom-reflux association was analyzed separately
for the first and second 24-h period of monitoring, a sig-
nificant difference was found in the number of patients
with positive SI [day 1: 68.5 %, (37/54) vs. day 2: 81.5 %
(44/54), difference: 12.96; 95 % CI 0.58–16.57;
P = 0.0391]. There was no difference between day 1 and
day 2 in the percentage of patients with positive SAP [day
1: 59.2 %, (32/54) vs. day 2: 63 %, (34/54), difference:
3.7 %; 95 % CI -12.83 to 18.98; P = 0.8145] (Fig. 2).
However, we found significant differences in the num-
ber of patients with positive SI or SAP on the first day and
after 2 days of monitoring. The percentage of patients with
positive SI was 68.5 % (37/54) on day 1 and 87.0 % (47/
54) on days 1 ? 2 (difference: 18.52 %; 95 % CI
2.58–27.23; P = 0.0213). The percentage of patients with
positive SAP was 59.2 % (32/54) on day 1 and 74.1 % (40/
54) on days 1 ? 2 (difference: 14.81 %, 95 % CI
0.7–21.29; P = 0.0386; Fig. 3).
Symptom-Reflux Association in Subgroups of Patients
Off and On PPI Therapy
No significant differences in the number of patients with
positive SI or SAP during the first 24 h and following
2 days of recording were found in patients on PPI therapy
upon analyzing the symptom-reflux association separately
in both the off- and on-PPI therapy subgroups of patients.
The percentage of patients tested on PPI therapy with
positive SI was 71.4 % (15/21) on day 1 and 81.0 % (17/
21) on days 1 ? 2 (difference: 9.52 %, 95 % CI -11.65 to
18.81, P = 0.6250). The percentage of patients tested on
PPI therapy with positive SAP was 66.7 % (14/21) on day
1 and 72.6 % (16/21) on days 1 ? 2 (difference: 9.52 %,
95 % CI -11.65 to 18.81, P = 0.6250). However, the
Table 1 Characteristics of reflux episodes




P Day 1 and day 2,
median (25–75 %)
Total reflux episodes 48 (36–73) 48 (34–67) 0.1231 97 (73–138)
Acidic reflux 24 (14–42) 21.5 (11–39) 0.0280 44.5 (27–79)
Weakly acidic reflux 17.5 (12–31) 17 (12–37) 0.2244 33 (25–53)
Weakly alkaline reflux 0 (0–1) 0 (0–2) 0.4799 1 (0–3)
Proximal reflux 22 (14–41) 23.5 (16–36) 0.8767 42 (27–75)
Fig. 1 Day-to-day distribution
of abnormal and normal total
acid exposure time and total
reflux episodes. n number of
patients
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difference in the percentage of patients with positive SI on
day 1 and days 1 ? 2 was significant in patients off PPI
therapy [24.4 %, day 1: 66.7 % (22/33) vs. days 1 ? 2:
90.9 % (30/33), 95 % CI 1.15–34.85, P = 0.0386]. The
difference in the percentage of patients tested off PPI
therapy with positive SAP on day 1 and days 1 ? 2 was
not significant [18.18 %, day 1: 54.5 % (18/33) vs. days
1 ? 2: 72.7 % (24/33), 95 % CI -1.29 to 24.09,
P = 0.0703].
Characteristics of Patients with Negative SI or SAP
on Day 1 and Positive SI or SAP on Days 1 ? 2
Out of the total number of patients, 13 (24.1 %) subjects
were found to have a negative SI on the first day of
assessment followed by a positive SI after 2 days of
monitoring. Only three of those 13 subjects were patients
Table 2 pH-MII parameters in relation to the duration of analysis and treatment with proton pump inhibitor





Duration of analysis (s)
Total 22 (21.2–22.52) 22.03 (21.02–22.36) 0.6620
Upright 12.04 (10.28–13.24) 12.17 (10.51–13.11) 0.8341
Recumbent 9.39 (8.53–10.81) 9.52 (8.46–11.29) 0.9709
AET total (%) 2.45 (0.7–5.3) 1.9 (0.6–4.4) 0.0974
ACT total (sec) 89.5 (38.0–161.0) 88.0 (46.0–130.0) 0.1201
BCT total (sec) 11.05(9.0–15.0) 11.0 (8.0–13.0) 0.7505
On PPI (n = 21)
AET total (%) 0.6 (0.0–2.1) 0.4 (0.1–0.8) 0.0677
ACT total (sec) 68.0 (24.0–92.0) 50.0 (37.0–93.0) 0.8077
BCT total (sec) 10.0 (7.0–15.0) 11.0 (8.0–13.0) 0.3103
Off PPI (n = 33)
AET total (%) 4.5 (1.4–7.6) 3.7 (2.0–6.0) 0.3301
ACT total (%) 132.0 (52.0–204.0) 95.0 (68.0–173.0) 0.2640
BCT total (%) 12.0 (10.0–15.0) 12.0 (9.0–13.0) 0.3895
AET acid exposure time, ACT acid clearance time, BCT bolus clearance time, PPI proton pump inhibitor
Fig. 2 Symptom-reflux
association in relation to the
duration of pH-MII monitoring.
SI symptom index, SI positive
C50 %, SI negative \50 %.
SAP symptom association
probability, SAP positive
C95 %, SAP negative \95 %
Fig. 3 Day-to-day distribution of positive and negative symptom-
reflux association: symptom index and symptom association proba-
bility. n number of patients, SI symptom index, SI positive C50 %.
SAP symptom association probability, SAP positive C95 %
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with refractory GERD symptoms tested on PPI therapy.
Among all the patients, ten individuals (18.5 %) had a
negative SAP on day 1 and a positive SAP after 2 days of
monitoring (Fig. 3). All patients with positive SAP also
had positive SI. Seven of those 10 (70 %) subjects were
patients off-PPI therapy and all had normal endoscopy
findings. Five of the above-mentioned seven patients had
abnormal acid exposure time and positive SAP for typical
symptoms in only one case, for both typical and atypical
symptoms (chest pain, cough, belching) in two cases, and
for atypical symptoms (cough, chest pain) in only two
patients. These patients were diagnosed as having NERD.
Two of the ten patients with positive SAP had symptoms
correlated with acidic reflux alone, three patients had
symptoms correlated with acidic and weakly acidic reflux,
and five patients with weakly acidic reflux alone.
Association of Symptoms of Different Types
with Reflux
In comparison to the one-day assessment, patients reported
a significantly increased number of various symptoms
correlated with reflux episodes (positive SAP) following
2 days of monitoring (Fig. 4).
Discussion
To the best of our knowledge, our study was the first to
demonstrate the potential of esophageal pH with imped-
ance monitoring recorded over a period of 48 h.
The sensitivity of catheter-based 24-h pH-metry is
limited by the day-to-day variability in AET, number of
reflux episodes, and the number of symptoms reported by
the patients [26]. It has been suggested that pH monitoring
using a wireless capsule generates less adverse symptoms
than the traditional catheter-based system [7–9, 27].
However, 10–40 % of patients investigated with a capsule-
based protocol experienced symptoms including chest
discomfort or foreign body sensation and up to 4 % of
them may require endoscopic removal of the capsule due to
severe chest pain. Additionally, endoscopy needs to be
performed to ensure the proper placement in the esophagus
and to assess the gastro-esophageal junction [7, 28–31].
Although a catheter-based study is not well tolerated in up
to 10 % of the patients and may affect activity, endoscopy
is not necessary. Furthermore, compared to the catheter-
based system, the wireless capsule is less available. Our
study showed that prolonging monitoring using pH-MII is
generally well tolerated. Minor adverse symptoms such as
throat pain and nasal discomfort were reported by 14.8 %
of the patients. However, 76 % of all patients stated that
they would undergo the test again.
Extending pH monitoring to 48 h by using a wireless
system improves the detection of abnormal AET by 22 %
and increases the sensitivity of the pH test [7, 8, 31, 32]. In
comparison, pH-MII monitoring allows for the identifica-
tion of all acidic, weakly acidic, and weakly alkaline reflux,
thereby increasing the diagnostic yield by 15–20 % [10–
13]. In our study, we did not demonstrate any significant
differences between the 2 days of pH-MII monitoring in
the percentage of patients with normal and abnormal
results of AET and reflux episode numbers.
An abnormal number of reflux episodes or increased
AET do not automatically imply that reflux is the cause of
the symptoms, and normal study does not exclude reflux as
a cause of the symptoms. In clinical practice, the assess-
ment of the association between reflux and symptoms is
more important. There are limitations to the most common
indices used for assessing the correlation [33]. SI is defined
as the percentage of symptoms that are reflux related,
regardless of the total number of reflux episodes. There-
fore, patients with a lower number of symptoms have a
higher probability of having positive SI. SAP was devel-
oped to overcome the limitations of SI [24, 25]. When a
patient reports single, rare symptoms, it is difficult or even
impossible to assess their correlation with reflux; even 24-h
monitoring may not be sufficient. A prolonged wireless pH
test improves the symptom-acid reflux correlation [8, 26,
31]. Our study demonstrated that the number of various
symptoms increased over time; therefore, indicating that
the 2-day test makes the symptom-reflux association more
useful. There were ten patients (18.5 %) with positive SAP
and 13 patients (24.1 %) with positive SI after 48 h that
had been negative in the first 24 h. Such results were
particularly evident in patients with atypical symptoms, in
whom a pH-MII test was performed to confirm or exclude
GERD as a cause of symptoms. We recognized NERD in
five of seven patients tested off PPI therapy and with
positive SAP only after 2 days of monitoring. In addition,
Fig. 4 The number of symptoms of different type with positive
symptom-reflux association in subgroups of patients off proton pump
inhibitor therapy. SI symptom index, SAP symptom association
probability
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four out of five of those patients had positive SAP for
atypical symptoms. Additionally, two patients met the
criteria for functional heartburn. Five out of ten patients
with positive SAP after 2 days of monitoring had symp-
toms correlated with weakly acidic reflux alone, which
would not be detected by 24- or 48-h pH study.
Taking into consideration potentially decreased oral
intake and physical activity during the catheter-based test,
as well as day-to-day variations in reflux episodes and
symptom numbers, prolonged monitoring may facilitate
diagnosis in patients with a negative 24-h pH study. Sweis
et al. [34] demonstrated that prolonged, wireless pH-
monitoring increases test sensitivity and diagnostic yield in
patients with continuing esophageal symptoms despite
negative 24-h catheter pH-studies and concluded that
without a definitive diagnosis many would not have
received effective treatment. In this study, a good outcome
was reported by ten out of 12 patients who underwent anti-
reflux surgery. Additionally, there is data demonstrating
the clinical usefulness of prolonged wireless pH monitoring
in off-PPI treatment evaluation [31, 35] and the pH-MII
test for better characterization of patients with persistent
symptoms despite PPI therapy [12–21, 36–38]. The utility
of prolonged pH-MII monitoring, including the period off
and on PPI therapy, might be an issue worthy of future
study.
Our study had a number of limitations. The time of
monitoring among the individual patients differed slightly,
although not significantly. All the patients that completed
2 days (2 nights) were included in the study; also, the
minimum time of recording (21 h for each scheduled 24 h
period) was achieved. However, there are no standard
values for the 48-h pH-impedance monitoring, and the
results of this study should be interpreted with caution.
Moreover, clinical significance of weakly acidic reflux
detected by pH-impedance test remains an area of contro-
versy. Most importantly, we should also take into consid-
eration that increasing the diagnostic yield of the study may
also increase false positives. Positive predictive values may
likely decrease with additional testing and may best serve
to exclude GERD [33]. Future studies should also evaluate
whether making symptom-reflux correlation analysis more
efficient can influence the effects of therapy.
In summary, our study demonstrated that prolonged
48-h pH-MII monitoring is possible and generally well
tolerated. Extending pH-MII monitoring to 2 days does not
improve the detection of abnormal acid exposure. How-
ever, it does increase the reported number of various
symptoms with positive reflux association and the fraction
of patients with positive SAP by as much as 18.5 %. It may
be considered in patients with normal endoscopy who
report rare or atypical symptoms in order to exclude or
confirm GERD as a causative factor. A direct comparison
of prolonged 48-h pH-impedance with wireless 48-h pH-
monitoring, that takes into account all their advantages and
disadvantages, should constitute the subject of future
studies.
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
The exclusive right to any commercial use of the article is with
Springer.
References
1. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h
esophageal pH monitoring: normal values, optimal thresholds,
specificity, sensitivity, and reproducibility. Am J Gastroenterol.
1992;87:1102–1111.
2. Wiener GJ, Morgan TM, Copper JB, et al. Ambulatory 24-hour
esophageal pH monitoring. Reproducibility and variability of pH
parameters. Dig Dis Sci. 1988;3:1127–1133.
3. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-
erosive reflux disease (NERD)-acid reflux and symptom patterns.
Aliment Pharmacol Ther. 2003;17:537–545.
4. Mearin F, Balboa A, Dot J, Maldonado O, Malagelada JR. How
standard is a standard day during a standard ambulatory 24-hour
esophageal pH monitoring? Scand J Gastroenterol. 1998;33:583–585.
5. Fass R, Hell R, Sampliner RE, et al. Effect of ambulatory 24-hour
esophageal pH monitoring on reflux-provoking activities. Dig Dis
Sci. 1999;44:2263–2269.
6. Hirano I, Richter JE. Practice parameters committee of the
American College of Gastroenterology. ACG practice guidelines:
esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.
7. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J,
Kahrilas PJ. Ambulatory esophageal pH monitoring using a
wireless system. Am J Gastroenterol. 2003;98:740–749.
8. Prakash C, Clouse RE. Value of extended recording time with
wireless pH monitoring in evaluating gastroesophageal reflux
disease. Clin Gastroenterol Hepatol.. 2005;3:329–334.
9. Sweis R, Fox M, Anggiansah R, et al. Patient acceptance and
clinical impact of Bravo monitoring in patients with previous
failed catheter-based studies. Aliment Pharmacol Ther. 2009;29:
669–676.
10. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux
monitoring: review and consensus report on detection and defini-
tions of acid, non-acid, and gas reflux. Gut. 2004;531024–1031.
11. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of
esophageal impedance monitoring to pH monitoring increases the
yield of symptom association analysis in patients off PPI therapy.
Am J Gastroenterol. 2006;101:453–459.
12. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance
monitoring and symptom analysis in GERD: a study in patients
off and on therapy. Am J Gastroenterol. 2006;101:1956–1963.
13. Blondeau K, Tack J. Pro: impedance testing is useful in the man-
agement of GERD. Am J Gastroenterol. 2009;104:2664–2666.
14. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in
patients with persistent symptoms despite acid suppressive ther-
apy: a multicentre study using combined ambulatory impedance-
pH monitoring. Gut. 2006;55:1398–1402.
2562 Dig Dis Sci (2013) 58:2556–2563
123
15. Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF,
Timmer R, Smout AJ. Esophageal pH-impedance monitoring in
patients with therapy-resistant reflux symptoms: ‘on’ or ‘off’ pro-
ton pump inhibitor? Am J Gastroenterol. 2008;103:2446–2453.
16. Sifrim D, Zerbib F. Diagnosis and management of patients with
reflux symptoms refractory to proton pump inhibitors. Gut. 2012;
61:1340–1354.
17. Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG,
Vaezi MF. Efficacy of esophageal impedance/pH monitoring in
patients with refractory gastroesophageal reflux disease, on and
off therapy. Clin Gastroenterol Hepatol. 2009;7:743–748.
18. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux
in NERD: lessons learned from impedance-pH monitoring in 150
patients off therapy. Am J Gastroenterol. 2008;103:2685–2693.
19. Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J.
Weakly acidic reflux in patients with chronic unexplained cough
during 24 hour pressure, pH, and impedance monitoring. Gut.
2005;54:449–454.
20. Blondeau K, Dupont LJ, Mertens V, Tack J, Sifrim D. Improved
diagnosis of gastro-oesophageal reflux in patients with unexplained
chronic cough. Aliment Pharmacol Ther. 2007;25:723–732.
21. Malhotra A, Freston JW, Aziz K. Use of pH-impedance testing to
evaluate patients with suspected extraesophageal manifestations
of gastroesophageal reflux disease. J Clin Gastroenterol. 2008;
42:271–278.
22. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory
simultaneous impedance and pH monitoring: a multicenter report
of normal values from 60 healthy volunteers. Am J Gastroenterol.
2004;99:1037–1043.
23. Tutuain R, Mainie I, Agrawal A, Freeman J, Castel DO. Normal
values for ambulatory 24-hour combined impedance-pH moni-
toring on acid suppressive therapy [abstract]. Gastroenterology.
2006;130:A171.
24. Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO. The
symptom index: a clinically important parameter of ambulatory
24-hour esophageal pH monitoring. Am J Gastroenterol. 1988;83:
358–361.
25. Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Hene-
gouwen GP, Smout AJ. The symptom-association probability: an
improved method for symptom analysis of 24-hour esophageal
pH data. Gastroenterology. 1994;107:1741–1745.
26. Scarpulla G, Camilleri S, Galante P, Manganaro M, Fox M. The
impact of prolonged pH measurements on the diagnosis of gas-
troesophageal reflux disease: 4-day wireless pH studies. Am J
Gastroenterol. 2007;102:2642–2647.
27. Wenner J, Johnsson F, Johansson J, Oberg S. Wireless esophageal
pH monitoring is better tolerated than the catheter-based tech-
nique: results from a randomized cross-over trial. Am J Gastro-
enterol. 2007;102:239–245.
28. Lee YC, Wang HP, Chiu HM, et al. Patients with functional
heartburn are more likely to report retrosternal discomfort during
wireless pH monitoring. Gastrointest Endosc. 2005;62:834–841.
29. Ahlawat SK, Novak DJ, Williams DC, Maher KA, Barton F,
Benjamin SB. Day-to-day variability in acid reflux patterns using
the BRAVO pH monitoring system. J Clin Gastroenterol. 2006;
40:20–24.
30. Remes-Troche JM, Ibarra-Palomino J, Carmona-Sa´nchez RI,
Valdovinos MA. Performance, tolerability, and symptoms related
to prolonged pH monitoring using the Bravo system in Mexico.
Am J Gastroenterol. 2005;100:2382–2386.
31. Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux
detection and symptom-reflux association using 4-day wireless
pH recording combining 48-hour periods off and on PPI therapy.
Am J Gastroenterol. 2008;103:1631–1637.
32. Tseng D, Rizvi AZ, Fennerty MB, et al. Forty-eight-hour pH
monitoring increases sensitivity in detecting abnormal esophageal
acid exposure. J Gastrointest Surg. 2005;9:1043–1051.
33. Connor J, Richter J. Increasing yield also increases false positives and
best serves to exclude GERD. Am J Gastroenterol. 2006;101:460–463.
34. Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless
pH-studies have a high diagnostic yield in patients with reflux
symptoms and negative 24-h catheter-based pH-studies. Neuro-
gastroenterol Motil. 2011;23:419–426.
35. Calabrese C, Liguori G, Gabusi V, et al. Ninety-six-hour wireless
oesophageal pH monitoring following proton pump inhibitor
administration in NERD patients. Aliment Pharmacol Ther. 2008;
28:250–255.
36. Sharma N, Agarwal A, Freeman J, Vela MF, Castell D. An analysis
of persistent symptoms in acid-suppressed patients undergoing
impedance-pH monitoring. Clin Gastroenterol Hepatol. 2008;6:
521–524.
37. Boeckxstaens GE, Smout A. Systematic review: role of acid,
weakly acidic and weakly alkaline reflux in gastro-oesophageal
reflux disease. Aliment Pharmacol Ther. 2010;32:334–343.
38. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A.
Clinical trial: persistent gastro-oesophageal reflux symptoms
despite standard therapy with proton pump inhibitors—a follow-
up study of intraluminal-impedance guided therapy. Aliment
Pharmacol Ther. 2007;26:1355–1360.
Dig Dis Sci (2013) 58:2556–2563 2563
123
